Board of Directors

Our Board of Directors

The Board of Directors is responsible for approving the corporate strategy, setting goals for the Executive Management, and evaluating management performance and qualifications. Further, the Board of Directors ensures adequate internal and external controls. In short, their function is to ensure sustainable value creation for all Lundbeck’s stakeholders – patients, stakeholders, and our employees.

Lars Søren Rasmussen

Chairman of the Board. Member, Audit Committee. Chairman, Remuneration & Nomination Committee. Born 1959.

Lars Søren Rasmussen, BSc Engineering and MBA, was born on 31 March 1959 and is a Danish citizen. He was nominated for election to H. Lundbeck A/S’ Board of Directors at the 2013 annual general meeting. He chairs H. Lundbeck A/S’ Remuneration & Nomination Committee and is a member of H. Lundbeck A/S' Audit Committee.

 

Lars Søren Rasmussen has considerable management experience in global med-tech. Lars Søren Rasmussen has most recently been CEO of Coloplast A/S from 2008 to 2018 and was a member of the company's executive management since 2001. During his time at Coloplast, Lars was responsible for various functions in the group, including global sales, innovation and production. He performed these duties from both Denmark and the US. Lars Rasmussen resigned his position as CEO of Coloplast A/S as of December 4th, 2018 and took over the position as Chairman of the Board of Directors of Coloplast A/S starting 5 December. 

 

Lars Søren Rasmussen's special qualifications for serving on H. Lundbeck A/S’ Board of Directors include his top management experience and knowledge of efficiency improvements and internationalisation. Lars Søren Rasmussen is Chairman of the Board of Directors in Coloplast A/S, Chairman of the Board of Directors in Igenomix S.L. and member of the Board of Directors of Demant A/S. He is also serving as Chairman of the DI (Danish Industry) Committee on Diversity and as Vice Chairman of the Danish Committee of Corporate Governance.  

Lene Skole-Sørensen

Deputy Chairman of the Board. Member, Remuneration & Nomination Committee. Member, Scientific Committee. Born 1959.

Lene Skole-Sørensen, BCom Finance, was born on 28 April 1959 and is a Danish citizen. She was nominated for election to H. Lundbeck A/S’ Board of Directors at the 2015 annual general meeting. She is a member of H. Lundbeck A/S’ Remuneration & Nomination Committee and Scientific Committee.

 

Lene Skole-Sørensen is CEO at the Lundbeck Foundation, CEO at Lundbeckfond Invest A/S and Chairman of the Board of Directors at LFI Equity A/S. Prior to joining the Lundbeck Foundation in 2014, Lene Skole-Sørensen was CFO at Coloplast A/S, where she was a member of the company’s executive management since joining in 2005. Lene Skole-Sørensen’s responsibilities included finance, IT, HR, communication, strategy and M&A. Before 2005, Lene Skole-Sørensen held various positions in the AP Moller-Maersk group, most recently as CFO of Maersk Company Ltd., London from 2000-2005.

 

Lene Skole-Sørensen’s special qualifications for serving on H. Lundbeck A/S’ Board of Directors include extensive knowledge and expertise within financing, strategy, business development and M&A as well as management experience from international companies including med-tech. 

 

Lene Skole-Sørensen is deputy Chairman of the Board of Directors of Ørsted A/S, Falck A/S, ALK-Abelló A/S, and member of the Board of Directors of Tryg A/S and Tryg Forsikring A/S.

Lars Erik Holmqvist

Member of the board. member, Audit Committee. Born 1959.

Lars Holmqvist, MSc in Business Administration, was born on 4 September 1959 and is a Swedish citizen. He was nominated for election to Lundbeck’s Board of Directors at the 2015 annual general meeting. He is a member of Lundbeck’s Audit Committee.

 

Lars Holmqvist was senior advisor within healthcare at Bain Capital Private Equity. He previously served as vice president responsible for sales and marketing at Pharmacia. In addition he has held management positions in several pharma and med-tech companies including Boston Scientific Corporation, Medtronic, Applied Biosystems Inc, DAKO A/S and Agilent Technologies.

 

Lars Holmqvist’s special qualifications for serving on Lundbeck`s Board of Directors include his international management experience, his expertise in finance, and his sales and marketing experience from the global pharmaceutical, med-tech and life-science industry.

 

Lars Holmqvist is Chairman of the Board of Directors for Biovica International AB and a member of the Board of Directors of the Lundbeck Foundation, ALK-Abelló A/S, Vitrolife AB, Tecan AG and Naka UK topco Ltd.

Jeremy Max Levin

member of the board. Chairman, Scientific Committee. Born 1953.

Jeremy Max Levin, BA Zoology, MA and DPhil in Molecular Biology and MB BChir Medicine and Surgery, was born on 9 September 1953 and is a British and US citizen. He was nominated for election to H. Lundbeck A/S’ Board of Directors at the 2017 annual general meeting. He chairs H. Lundbeck A/S’ Scientific Committee. 

 

Dr. Levin has more than 25 years of experience in the global pharmaceuticals industry, leading companies and people to develop and commercialize medicines that address compelling medical needs worldwide. Since 2014, he has been CEO and Chairman of Ovid Therapeutics, a New York based neurology company focused on rare and orphan diseases of the brain. Previously, Dr. Levin served as President & CEO of Teva Pharmaceuticals and before becoming CEO of Teva, he was a member of the Executive Committee of Bristol-Myers Squibb where he was globally responsible for overall strategy, alliances and business development. Prior to that, he was Global Head of Strategic Alliances at Novartis, where he established and managed strategic collaborations with multiple companies and research institutions around the world.

 

Dr. Levin’s special qualifications for serving on H. Lundbeck A/S’ Board of Directors include a robust blend of clinical insight and experience, business development skills, corporate strategy and financial savvy. In addition, he has substantial board experience.  

 

In addition to Ovid Therapeutics, Dr. Levin is Chairman of the Board of Directors of BIO (the Biotechnology Innovation Organization based in the USA) and is  Chairman of the Board of Directors of Opthea (based in Australia).

Jeffrey Berkowitz

member of the board. Member, Remuneration & Nomination Committee. Member, Scientific Committee. Born 1966.

Jeffrey Berkowitz, Juris Doctor and BA in Political Science, was born on 9 January 1966 and is a US citizen. He was nominated for election to  the H. Lundbeck A/S’ Board of Directors at the 2018 annual general meeting and is a member of the Scientific Committee and since March 2019 a member of the Remuneration & Nomination Committee.

 

Jeffrey Berkowitz is currently the CEO of Real Endpoints, a leader in the development and implementation of proprietary tools to strengthen market access for biopharmaceutical companies. Prior to this, Jeffrey Berkowitz has recently served as an Executive Vice President of UnitedHealth Group (UNH), and CEO of their Optum International subsidiary since 2016. He served as an Executive Committee member and President of Pharma & Global Market Access at Walgreens Boots Alliance, Inc. from 2014 and served first as Senior Vice President of Pharmaceutical Development and Market Access of Walgreen Co, then as President of Walgreens Boots Alliance Development in the period 2010 to 2015. From 1998 to 2010, he held a variety of positions with increasing responsibility in market access, sales and marketing with Schering-Plough prior to its acquisition by Merck in 2009. Prior to joining Schering-Plough, Jeffrey Berkowitz was a health care attorney for the international law firm Proskauer, LLP in New York and Washington, D.C.

 

Jeffrey Berkowitz’s special qualifications for serving on H. Lundbeck A/S’ Board of Directors include proven results and global experience with payers, pharmaceutical companies, specialty and retail pharmacies and drug distributors with deep experience in generic and branded procurement and inventory management, as well as pricing, reimbursement, specialty pharmacy distribution and health care strategies. He is a sought after thought leader and speaker in the area of pharmaceutical market access and reimbursement and has extensive public board and committee experience.

 

Jeffrey Berkowitz is an independent director of Esperion Therapeutics, Inc. (ESPR), and a member of the Board of Directors of Zealand Pharma A/S (ZEAL) and Uniphar PLC (UPR).

Dorothea Wenzel

member of the board. Chairman, Audit Committee. Born 1969.

Dorothea Wenzel holds a PhD in Health Economics and Macroeconomics from the University of Darmstadt in Germany. She has also held fellowships at Harvard and was a visiting student at University of California at Berkley. She was nominated for election to H. Lundbeck A/S' Board of Directors at the 2021 Annual General Meeting.

 

Dorothea Wenzel, a German national, has had a long career at Merck KGaA, headquartered in Darmstadt, Germany. She currently serves as Executive Vice President and Head of the Global Business Unit Surface Solutions. Prior to her current role, she was CFO of Merck’s Performance Materials division and Head of Strategy & Controlling. In that role, she transformed the division’s Controlling function and was instrumental in creating the division’s business strategy. Prior to that, she led Merck’s Fertility franchise to growth.

 

Dorothea's special qualifications for serving on H. Lundbeck A/S’ Board of Directors include an impressive track record in Finance and Strategy leadership across multiple industries. Dorothea will further strengthen the Board's competencies in finance and business transformation to ensure the company remains best set for the future. 

 

In addition to her role at Merck, she currently serves on the Supervisory Board of Fresenius Medical Care AG & Co. KGaA.

Santiago Arroyo

member of the board. member, Scientific committee. born 1960.

Dr. Santiago Arroyo received his medical degree from the Autonomous University of Madrid and his Ph.D. from the University of Barcelona, Spain. He is born on 2 June 1960 and is a US citizen. He is nominated for election to H. Lundbeck A/S’ Board of Directors at the 2021 Annual General Meeting.

 

Dr. Arroyo brings with him more than 30 years of experience in academic neurology and pharmaceutical research and development. As an academic neurologist, Dr. Arroyo held faculty positions at the Johns Hopkins Hospital, Hospital Clinic of Barcelona and the Medical College of Wisconsin where he was Associate Professor of Neurology. He has special expertise in pediatric and adult epilepsy and electrophysiology.In 2003, Dr. Arroyo joined the pharmaceutical industry and has held a variety of positions with increasing responsibility in clinical research and development. Most recently, he served as Chief Medical Officer of Momenta Pharmaceuticals, a biotechnology company located in Massachusetts, USA, focusing on discovering and developing novel therapeutics to treat rare, immune-mediated diseases. The company was acquired in 2020 by Johnson & Johnson. Prior to his role at Momenta Pharmaceuticals, Dr. Arroyo served as Chief Medical Officer of Boston Pharmaceuticals focusing on the therapeutic areas of immunoscience, oncology and infectious diseases. Dr. Arroyo also held the roles of Senior Vice President, Head of Clinical Research and Chief Medical Officer of Biotherapeutics and Pharmatherapeutics at Pfizer Inc. in the areas of Neurology, Psychiatry Pain, Cardiovascular and Metabolism, Regenerative Medicine and Rare Diseases. He was Therapeutic Area Head for Neurosciences, Discovery Medicine and Clinical Pharmacology at Bristol-Myers Squibb and Neurology Global Therapeutic Area Head for Eisai Global Clinical Development.

 

Dr. Arroyo’s special qualifications for serving on H. Lundbeck A/S’ Board of Directors include his therapeutic and deep scientific expertise in neuroscience and beyond as well as strategic and business vision. His leadership roles in academic and pharmaceutical areas, combined with more recent biotech experience and success, provide a solid platform for adding scientific and business development perspectives to H. Lundbeck A/S’ future path.

Henrik Sindal Jensen

Employee representative. Born 1969.

Henrik Sindal Jensen, BSc Chemistry, MSc Molecular Biology and PhD Neuroscience, was born on 15 December 1969 and is a Danish citizen.

 

Henrik has been employed with Lundbeck since 2004 and currently holds a position as Director in Corporate Business Development & Licensing.  Before this, Henrik worked in research where he held a number of different positions including line and project management and most recently as Principal Scientist involved Lundbeck’s research projects.

 

Henrik obtained his BSc and MSc degrees from the University of Aarhus and earned his industrial PhD degree in collaboration between the Graduate School of Neuroscience at the University of Copenhagen and NeuroSearch. Prior to joining Lundbeck, Henrik held positions as Assistant Professor at the Department of Medical Physiology, University of Copenhagen and as Research Assistant at the Department of Molecular and Structural Biology, University of Aarhus.

Rikke Kruse Andreasen

Employee representative. Born 1971.

Rikke Kruse Andreasen, Laboratory Technician, was born in 1971 and is a Danish citizen.

 

Rikke has been with Lundbeck since 1995 as a Senior Laboratory Technician. In 2012, she was elected as a Union Representative for the laboratory technicians and as a Work Council member.

 

She is educated as a Laboratory Technician in 1991 at Laborantskolen Copenhagen, and in 2016 she completed a college education in Employment Law and Negotiation at Copenhagen Business School.

 

Rikke Kruse Andreasen started working with Statens Serum Institut from 1991-1995 as Section Laboratory Technician. Since working with Lundbeck, she has been in three different departments as a Senior Laboratory Technician.

Ludovic Tranholm Otterbein

Employee representative. Born 1973.

Ludovic Tranholm Otterbein, MSc Molecular Biology and PhD, was born on 12 November 1973 and is a French citizen.  

 

Ludovic has been with Lundbeck since 2011 and started as an external Lean Consultant. In his current role, Ludovic is heading R&D solution architect group part of Corporate IT.

 

Ludovic completed his MSc in France in 1998 at Polytech Marseille, before moving to the United States of America to complete his PhD in Biophysics working on muscular diseases. Before joining Lundbeck, Ludovic was a Senior Consultant at Valeocon Management Consulting where he helped clients within the pharmaceutical industry. Ludovic has also worked at AstraZeneca both in UK and Sweden from 2002-2010. 

More from Lundbeck

Our Commitment

We strive for Progress in Mind - our multifaceted approach to patients.

Business Development

Partnerships are a key pillar in our strategy to become leaders in brain health.

Our Strategy

Our strategy “Expand and Invest to Grow” aims to deliver sustainable growth.